China Mandates Driving Warning on Ganmaoling Cold Medicine

China's National Medical Products Administration (NMPA) has issued a directive requiring all oral formulations of the popular cold medicine "Ganmaoling" to include a mandatory warning in their instructions. Effective July 20, the updated labeling will state: "Do not operate motor vehicles, land vehicles, or vessels while taking the medication."

The decision stems from the potential side effects of Ganmaoling's ingredients. The medicine is a combination of Western pharmaceuticals, including acetaminophen, chlorpheniramine maleate, and caffeine. Chlorpheniramine maleate, in particular, can cause drowsiness, fatigue, and reduced concentration, which can impair driving ability and judgment. Acetaminophen, while generally safe, can cause severe skin reactions in rare cases.

The NMPA's move aims to bolster patient safety by ensuring individuals are aware of potential impairments that could affect their ability to operate machinery, including vehicles. This regulatory update aligns with global trends in pharmaceutical labeling to clearly communicate risks associated with medication use.

Industry observers suggest the labeling change is unlikely to significantly impact overall sales of Ganmaoling. The medication is typically used for short-term symptom relief, distinct from chronic condition treatments. Furthermore, the market offers alternative cold remedies without sedative side effects, catering to drivers and individuals in safety-sensitive occupations.